|
?:abstract
|
-
BACKGROUND: Since its initial start on December 2019 at Wuhan, China, the coronavirus disease 2019 (COVID-19) has been rapidly spreading and labelled as pandemic by World Health Organization. The rate of human to human transmission of COVID-19 is far higher than severe acute respiratory syndrome (SARS) and Middle East respiratory syn-drome coronavirus (MERS). With no drugs or vaccines approved for the treatment of the disease, physicians have been using the pre-existing drugs to curb the disease. One potential anti-viral agent currently undergoing numerous clinical trial is remdesivir, a nucleotide analog that inhibits RNA-dependent RNA polymerase of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). OBJECTIVE: In this mini-review, we provide an overview of remdesivir\'s journey, mechanism of action, pharmacokinetics, used in patients with COVID-19 under compassionate use principle and clinical trials to understand the effect of remdesivir in the treatment of patients with COVID-19. CONCLUSION: Initially, remdesivir was granted an emergency use authorization ( EUA) by the U.S. Food and Drug Admin-istration for the treatment of COVID-19 with severe disease. But now, remdesivir has been granted for use under EUA to treat all hospitalized COVID-19 patients, irrespective of their severity of disease.
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}